nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbamazepine—RALBP1—Vincristine—lymphatic system cancer	0.402	0.502	CbGbCtD
Carbamazepine—CYP1A2—Carmustine—lymphatic system cancer	0.0486	0.0606	CbGbCtD
Carbamazepine—CYP3A5—Teniposide—lymphatic system cancer	0.0439	0.0548	CbGbCtD
Carbamazepine—ABCC2—Vincristine—lymphatic system cancer	0.0421	0.0526	CbGbCtD
Carbamazepine—CYP2C19—Teniposide—lymphatic system cancer	0.0354	0.0442	CbGbCtD
Carbamazepine—CYP2C9—Teniposide—lymphatic system cancer	0.0294	0.0367	CbGbCtD
Carbamazepine—CYP3A7—Vincristine—lymphatic system cancer	0.0281	0.0351	CbGbCtD
Carbamazepine—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0281	0.0351	CbGbCtD
Carbamazepine—ABCC2—Methotrexate—lymphatic system cancer	0.0255	0.0319	CbGbCtD
Carbamazepine—CYP3A5—Vincristine—lymphatic system cancer	0.0211	0.0264	CbGbCtD
Carbamazepine—ABCB1—Mitoxantrone—lymphatic system cancer	0.02	0.0249	CbGbCtD
Carbamazepine—CYP3A4—Cytarabine—lymphatic system cancer	0.0174	0.0217	CbGbCtD
Carbamazepine—CYP3A4—Teniposide—lymphatic system cancer	0.0171	0.0214	CbGbCtD
Carbamazepine—ABCB1—Vincristine—lymphatic system cancer	0.0137	0.0172	CbGbCtD
Carbamazepine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.012	0.0149	CbGbCtD
Carbamazepine—ABCB1—Methotrexate—lymphatic system cancer	0.00832	0.0104	CbGbCtD
Carbamazepine—CYP3A4—Vincristine—lymphatic system cancer	0.00823	0.0103	CbGbCtD
Carbamazepine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000258	0.00129	CcSEcCtD
Carbamazepine—Alopecia—Mitoxantrone—lymphatic system cancer	0.000256	0.00129	CcSEcCtD
Carbamazepine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000256	0.00129	CcSEcCtD
Carbamazepine—Confusional state—Bleomycin—lymphatic system cancer	0.000256	0.00129	CcSEcCtD
Carbamazepine—Vision blurred—Carmustine—lymphatic system cancer	0.000256	0.00129	CcSEcCtD
Carbamazepine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000255	0.00128	CcSEcCtD
Carbamazepine—Tremor—Carmustine—lymphatic system cancer	0.000255	0.00128	CcSEcCtD
Carbamazepine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000254	0.00128	CcSEcCtD
Carbamazepine—Oedema—Bleomycin—lymphatic system cancer	0.000254	0.00128	CcSEcCtD
Carbamazepine—Erythema—Mitoxantrone—lymphatic system cancer	0.000253	0.00127	CcSEcCtD
Carbamazepine—Infection—Bleomycin—lymphatic system cancer	0.000252	0.00127	CcSEcCtD
Carbamazepine—Anaemia—Carmustine—lymphatic system cancer	0.000251	0.00126	CcSEcCtD
Carbamazepine—Back pain—Vincristine—lymphatic system cancer	0.000251	0.00126	CcSEcCtD
Carbamazepine—Vomiting—Teniposide—lymphatic system cancer	0.000251	0.00126	CcSEcCtD
Carbamazepine—Agitation—Carmustine—lymphatic system cancer	0.00025	0.00125	CcSEcCtD
Carbamazepine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000249	0.00125	CcSEcCtD
Carbamazepine—Asthenia—Fludarabine—lymphatic system cancer	0.000249	0.00125	CcSEcCtD
Carbamazepine—Rash—Teniposide—lymphatic system cancer	0.000249	0.00125	CcSEcCtD
Carbamazepine—Dermatitis—Teniposide—lymphatic system cancer	0.000248	0.00125	CcSEcCtD
Carbamazepine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000247	0.00124	CcSEcCtD
Carbamazepine—Headache—Teniposide—lymphatic system cancer	0.000247	0.00124	CcSEcCtD
Carbamazepine—Pruritus—Fludarabine—lymphatic system cancer	0.000245	0.00123	CcSEcCtD
Carbamazepine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000245	0.00123	CcSEcCtD
Carbamazepine—Back pain—Mitoxantrone—lymphatic system cancer	0.000244	0.00123	CcSEcCtD
Carbamazepine—Leukopenia—Carmustine—lymphatic system cancer	0.000243	0.00122	CcSEcCtD
Carbamazepine—Anorexia—Bleomycin—lymphatic system cancer	0.000242	0.00122	CcSEcCtD
Carbamazepine—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000241	0.00121	CcSEcCtD
Carbamazepine—Anaemia—Vincristine—lymphatic system cancer	0.00024	0.0012	CcSEcCtD
Carbamazepine—Agitation—Vincristine—lymphatic system cancer	0.000238	0.0012	CcSEcCtD
Carbamazepine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000238	0.0012	CcSEcCtD
Carbamazepine—Polyuria—Methotrexate—lymphatic system cancer	0.000238	0.0012	CcSEcCtD
Carbamazepine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000238	0.0012	CcSEcCtD
Carbamazepine—Hypotension—Bleomycin—lymphatic system cancer	0.000237	0.00119	CcSEcCtD
Carbamazepine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000237	0.00119	CcSEcCtD
Carbamazepine—Convulsion—Carmustine—lymphatic system cancer	0.000235	0.00118	CcSEcCtD
Carbamazepine—Hypertension—Carmustine—lymphatic system cancer	0.000235	0.00118	CcSEcCtD
Carbamazepine—Nausea—Teniposide—lymphatic system cancer	0.000234	0.00118	CcSEcCtD
Carbamazepine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000233	0.00117	CcSEcCtD
Carbamazepine—Vertigo—Vincristine—lymphatic system cancer	0.000233	0.00117	CcSEcCtD
Carbamazepine—Hepatic failure—Methotrexate—lymphatic system cancer	0.000233	0.00117	CcSEcCtD
Carbamazepine—Leukopenia—Vincristine—lymphatic system cancer	0.000232	0.00117	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000231	0.00116	CcSEcCtD
Carbamazepine—Chest pain—Carmustine—lymphatic system cancer	0.000231	0.00116	CcSEcCtD
Carbamazepine—Myalgia—Carmustine—lymphatic system cancer	0.000231	0.00116	CcSEcCtD
Carbamazepine—Anxiety—Carmustine—lymphatic system cancer	0.00023	0.00116	CcSEcCtD
Carbamazepine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000228	0.00115	CcSEcCtD
Carbamazepine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000226	0.00114	CcSEcCtD
Carbamazepine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000226	0.00114	CcSEcCtD
Carbamazepine—Convulsion—Vincristine—lymphatic system cancer	0.000225	0.00113	CcSEcCtD
Carbamazepine—Hypertension—Vincristine—lymphatic system cancer	0.000224	0.00112	CcSEcCtD
Carbamazepine—Confusional state—Carmustine—lymphatic system cancer	0.000224	0.00112	CcSEcCtD
Carbamazepine—Oedema—Carmustine—lymphatic system cancer	0.000222	0.00111	CcSEcCtD
Carbamazepine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000221	0.00111	CcSEcCtD
Carbamazepine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000221	0.00111	CcSEcCtD
Carbamazepine—Myalgia—Vincristine—lymphatic system cancer	0.000221	0.00111	CcSEcCtD
Carbamazepine—Infection—Carmustine—lymphatic system cancer	0.00022	0.00111	CcSEcCtD
Carbamazepine—Vomiting—Fludarabine—lymphatic system cancer	0.00022	0.00111	CcSEcCtD
Carbamazepine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000219	0.0011	CcSEcCtD
Carbamazepine—Rash—Fludarabine—lymphatic system cancer	0.000218	0.0011	CcSEcCtD
Carbamazepine—Dermatitis—Fludarabine—lymphatic system cancer	0.000218	0.0011	CcSEcCtD
Carbamazepine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000218	0.0011	CcSEcCtD
Carbamazepine—Pain—Bleomycin—lymphatic system cancer	0.000217	0.00109	CcSEcCtD
Carbamazepine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000217	0.00109	CcSEcCtD
Carbamazepine—Headache—Fludarabine—lymphatic system cancer	0.000217	0.00109	CcSEcCtD
Carbamazepine—Tachycardia—Carmustine—lymphatic system cancer	0.000216	0.00109	CcSEcCtD
Carbamazepine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000215	0.00108	CcSEcCtD
Carbamazepine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000215	0.00108	CcSEcCtD
Carbamazepine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000215	0.00108	CcSEcCtD
Carbamazepine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000214	0.00108	CcSEcCtD
Carbamazepine—Lethargy—Methotrexate—lymphatic system cancer	0.000213	0.00107	CcSEcCtD
Carbamazepine—Oedema—Vincristine—lymphatic system cancer	0.000212	0.00106	CcSEcCtD
Carbamazepine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000212	0.00106	CcSEcCtD
Carbamazepine—Anorexia—Carmustine—lymphatic system cancer	0.000211	0.00106	CcSEcCtD
Carbamazepine—Infection—Vincristine—lymphatic system cancer	0.00021	0.00106	CcSEcCtD
Carbamazepine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000209	0.00105	CcSEcCtD
Carbamazepine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000209	0.00105	CcSEcCtD
Carbamazepine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000208	0.00104	CcSEcCtD
Carbamazepine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000208	0.00104	CcSEcCtD
Carbamazepine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000207	0.00104	CcSEcCtD
Carbamazepine—Hypotension—Carmustine—lymphatic system cancer	0.000207	0.00104	CcSEcCtD
Carbamazepine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000206	0.00104	CcSEcCtD
Carbamazepine—Oedema—Mitoxantrone—lymphatic system cancer	0.000206	0.00104	CcSEcCtD
Carbamazepine—Nausea—Fludarabine—lymphatic system cancer	0.000206	0.00103	CcSEcCtD
Carbamazepine—Infection—Mitoxantrone—lymphatic system cancer	0.000205	0.00103	CcSEcCtD
Carbamazepine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000205	0.00103	CcSEcCtD
Carbamazepine—Shock—Mitoxantrone—lymphatic system cancer	0.000203	0.00102	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000202	0.00101	CcSEcCtD
Carbamazepine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000202	0.00101	CcSEcCtD
Carbamazepine—Urticaria—Bleomycin—lymphatic system cancer	0.000202	0.00101	CcSEcCtD
Carbamazepine—Anorexia—Vincristine—lymphatic system cancer	0.000202	0.00101	CcSEcCtD
Carbamazepine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000201	0.00101	CcSEcCtD
Carbamazepine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000201	0.00101	CcSEcCtD
Carbamazepine—Insomnia—Carmustine—lymphatic system cancer	0.000201	0.00101	CcSEcCtD
Carbamazepine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.0002	0.00101	CcSEcCtD
Carbamazepine—Irritability—Methotrexate—lymphatic system cancer	0.000199	0.001	CcSEcCtD
Carbamazepine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000199	0.001	CcSEcCtD
Carbamazepine—Paraesthesia—Carmustine—lymphatic system cancer	0.000199	0.001	CcSEcCtD
Carbamazepine—Hypotension—Vincristine—lymphatic system cancer	0.000198	0.000993	CcSEcCtD
Carbamazepine—Dyspnoea—Carmustine—lymphatic system cancer	0.000198	0.000993	CcSEcCtD
Carbamazepine—Somnolence—Carmustine—lymphatic system cancer	0.000197	0.00099	CcSEcCtD
Carbamazepine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000196	0.000987	CcSEcCtD
Carbamazepine—Ataxia—Methotrexate—lymphatic system cancer	0.000196	0.000987	CcSEcCtD
Carbamazepine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000193	0.000969	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000193	0.000968	CcSEcCtD
Carbamazepine—Decreased appetite—Carmustine—lymphatic system cancer	0.000193	0.000968	CcSEcCtD
Carbamazepine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000193	0.000967	CcSEcCtD
Carbamazepine—Insomnia—Vincristine—lymphatic system cancer	0.000191	0.000961	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000191	0.000961	CcSEcCtD
Carbamazepine—Paraesthesia—Vincristine—lymphatic system cancer	0.00019	0.000954	CcSEcCtD
Carbamazepine—Pain—Carmustine—lymphatic system cancer	0.00019	0.000952	CcSEcCtD
Carbamazepine—Constipation—Carmustine—lymphatic system cancer	0.00019	0.000952	CcSEcCtD
Carbamazepine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000188	0.000945	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000188	0.000943	CcSEcCtD
Carbamazepine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000187	0.00094	CcSEcCtD
Carbamazepine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000185	0.00093	CcSEcCtD
Carbamazepine—Decreased appetite—Vincristine—lymphatic system cancer	0.000184	0.000924	CcSEcCtD
Carbamazepine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000184	0.000923	CcSEcCtD
Carbamazepine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000183	0.00092	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000183	0.000918	CcSEcCtD
Carbamazepine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000183	0.000918	CcSEcCtD
Carbamazepine—Fatigue—Vincristine—lymphatic system cancer	0.000182	0.000916	CcSEcCtD
Carbamazepine—Asthenia—Bleomycin—lymphatic system cancer	0.000182	0.000915	CcSEcCtD
Carbamazepine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000181	0.000911	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000181	0.000911	CcSEcCtD
Carbamazepine—Constipation—Vincristine—lymphatic system cancer	0.000181	0.000909	CcSEcCtD
Carbamazepine—Pain—Vincristine—lymphatic system cancer	0.000181	0.000909	CcSEcCtD
Carbamazepine—Pruritus—Bleomycin—lymphatic system cancer	0.00018	0.000902	CcSEcCtD
Carbamazepine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000179	0.0009	CcSEcCtD
Carbamazepine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000179	0.000898	CcSEcCtD
Carbamazepine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000178	0.000892	CcSEcCtD
Carbamazepine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000177	0.000889	CcSEcCtD
Carbamazepine—Constipation—Mitoxantrone—lymphatic system cancer	0.000176	0.000885	CcSEcCtD
Carbamazepine—Pain—Mitoxantrone—lymphatic system cancer	0.000176	0.000885	CcSEcCtD
Carbamazepine—Abdominal pain—Carmustine—lymphatic system cancer	0.000175	0.00088	CcSEcCtD
Carbamazepine—Body temperature increased—Carmustine—lymphatic system cancer	0.000175	0.00088	CcSEcCtD
Carbamazepine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000173	0.000869	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000173	0.000869	CcSEcCtD
Carbamazepine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000172	0.000861	CcSEcCtD
Carbamazepine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00017	0.000853	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000169	0.000846	CcSEcCtD
Carbamazepine—Abdominal pain—Vincristine—lymphatic system cancer	0.000167	0.00084	CcSEcCtD
Carbamazepine—Body temperature increased—Vincristine—lymphatic system cancer	0.000167	0.00084	CcSEcCtD
Carbamazepine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000166	0.000835	CcSEcCtD
Carbamazepine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000165	0.000828	CcSEcCtD
Carbamazepine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000164	0.000822	CcSEcCtD
Carbamazepine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000163	0.00082	CcSEcCtD
Carbamazepine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000163	0.000818	CcSEcCtD
Carbamazepine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000163	0.000818	CcSEcCtD
Carbamazepine—Pneumonia—Methotrexate—lymphatic system cancer	0.000162	0.000813	CcSEcCtD
Carbamazepine—Vomiting—Bleomycin—lymphatic system cancer	0.000162	0.000811	CcSEcCtD
Carbamazepine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000161	0.000809	CcSEcCtD
Carbamazepine—Infestation—Methotrexate—lymphatic system cancer	0.000161	0.000809	CcSEcCtD
Carbamazepine—Drowsiness—Methotrexate—lymphatic system cancer	0.000161	0.000809	CcSEcCtD
Carbamazepine—Depression—Methotrexate—lymphatic system cancer	0.000161	0.000806	CcSEcCtD
Carbamazepine—Rash—Bleomycin—lymphatic system cancer	0.00016	0.000804	CcSEcCtD
Carbamazepine—Dermatitis—Bleomycin—lymphatic system cancer	0.00016	0.000804	CcSEcCtD
Carbamazepine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00016	0.000802	CcSEcCtD
Carbamazepine—Asthenia—Carmustine—lymphatic system cancer	0.000159	0.000799	CcSEcCtD
Carbamazepine—Renal failure—Methotrexate—lymphatic system cancer	0.000158	0.000795	CcSEcCtD
Carbamazepine—Stomatitis—Methotrexate—lymphatic system cancer	0.000157	0.000788	CcSEcCtD
Carbamazepine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000157	0.000786	CcSEcCtD
Carbamazepine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000156	0.000783	CcSEcCtD
Carbamazepine—Haematuria—Methotrexate—lymphatic system cancer	0.000154	0.000771	CcSEcCtD
Carbamazepine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000152	0.000765	CcSEcCtD
Carbamazepine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000152	0.000763	CcSEcCtD
Carbamazepine—Asthenia—Vincristine—lymphatic system cancer	0.000152	0.000763	CcSEcCtD
Carbamazepine—Diarrhoea—Carmustine—lymphatic system cancer	0.000152	0.000762	CcSEcCtD
Carbamazepine—Nausea—Bleomycin—lymphatic system cancer	0.000151	0.000758	CcSEcCtD
Carbamazepine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00015	0.000755	CcSEcCtD
Carbamazepine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000148	0.000743	CcSEcCtD
Carbamazepine—Dizziness—Carmustine—lymphatic system cancer	0.000147	0.000736	CcSEcCtD
Carbamazepine—Diarrhoea—Vincristine—lymphatic system cancer	0.000145	0.000727	CcSEcCtD
Carbamazepine—Hepatitis—Methotrexate—lymphatic system cancer	0.000145	0.000726	CcSEcCtD
Carbamazepine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000143	0.00072	CcSEcCtD
Carbamazepine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000143	0.000717	CcSEcCtD
Carbamazepine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000142	0.000712	CcSEcCtD
Carbamazepine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000141	0.000708	CcSEcCtD
Carbamazepine—Vomiting—Carmustine—lymphatic system cancer	0.000141	0.000708	CcSEcCtD
Carbamazepine—Dizziness—Vincristine—lymphatic system cancer	0.00014	0.000703	CcSEcCtD
Carbamazepine—Rash—Carmustine—lymphatic system cancer	0.00014	0.000702	CcSEcCtD
Carbamazepine—Dermatitis—Carmustine—lymphatic system cancer	0.00014	0.000701	CcSEcCtD
Carbamazepine—Headache—Carmustine—lymphatic system cancer	0.000139	0.000698	CcSEcCtD
Carbamazepine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000137	0.000686	CcSEcCtD
Carbamazepine—Eye disorder—Methotrexate—lymphatic system cancer	0.000135	0.000678	CcSEcCtD
Carbamazepine—Tinnitus—Methotrexate—lymphatic system cancer	0.000135	0.000677	CcSEcCtD
Carbamazepine—Vomiting—Vincristine—lymphatic system cancer	0.000135	0.000676	CcSEcCtD
Carbamazepine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000134	0.000674	CcSEcCtD
Carbamazepine—Rash—Vincristine—lymphatic system cancer	0.000133	0.00067	CcSEcCtD
Carbamazepine—Dermatitis—Vincristine—lymphatic system cancer	0.000133	0.00067	CcSEcCtD
Carbamazepine—Headache—Vincristine—lymphatic system cancer	0.000133	0.000666	CcSEcCtD
Carbamazepine—Nausea—Carmustine—lymphatic system cancer	0.000132	0.000661	CcSEcCtD
Carbamazepine—Angiopathy—Methotrexate—lymphatic system cancer	0.000131	0.000659	CcSEcCtD
Carbamazepine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000131	0.000658	CcSEcCtD
Carbamazepine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000131	0.000656	CcSEcCtD
Carbamazepine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00013	0.000654	CcSEcCtD
Carbamazepine—Rash—Mitoxantrone—lymphatic system cancer	0.00013	0.000653	CcSEcCtD
Carbamazepine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00013	0.000652	CcSEcCtD
Carbamazepine—Chills—Methotrexate—lymphatic system cancer	0.00013	0.000651	CcSEcCtD
Carbamazepine—Headache—Mitoxantrone—lymphatic system cancer	0.000129	0.000648	CcSEcCtD
Carbamazepine—Alopecia—Methotrexate—lymphatic system cancer	0.000128	0.000641	CcSEcCtD
Carbamazepine—Mental disorder—Methotrexate—lymphatic system cancer	0.000127	0.000636	CcSEcCtD
Carbamazepine—Erythema—Methotrexate—lymphatic system cancer	0.000126	0.000632	CcSEcCtD
Carbamazepine—Malnutrition—Methotrexate—lymphatic system cancer	0.000126	0.000632	CcSEcCtD
Carbamazepine—Nausea—Vincristine—lymphatic system cancer	0.000126	0.000631	CcSEcCtD
Carbamazepine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000123	0.000619	CcSEcCtD
Carbamazepine—Nausea—Mitoxantrone—lymphatic system cancer	0.000122	0.000615	CcSEcCtD
Carbamazepine—Back pain—Methotrexate—lymphatic system cancer	0.000122	0.000611	CcSEcCtD
Carbamazepine—Vision blurred—Methotrexate—lymphatic system cancer	0.000119	0.000596	CcSEcCtD
Carbamazepine—Anaemia—Methotrexate—lymphatic system cancer	0.000116	0.000584	CcSEcCtD
Carbamazepine—Vertigo—Methotrexate—lymphatic system cancer	0.000113	0.000568	CcSEcCtD
Carbamazepine—Leukopenia—Methotrexate—lymphatic system cancer	0.000113	0.000566	CcSEcCtD
Carbamazepine—Convulsion—Methotrexate—lymphatic system cancer	0.000109	0.000548	CcSEcCtD
Carbamazepine—Chest pain—Methotrexate—lymphatic system cancer	0.000107	0.000538	CcSEcCtD
Carbamazepine—Arthralgia—Methotrexate—lymphatic system cancer	0.000107	0.000538	CcSEcCtD
Carbamazepine—Myalgia—Methotrexate—lymphatic system cancer	0.000107	0.000538	CcSEcCtD
Carbamazepine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000106	0.000534	CcSEcCtD
Carbamazepine—Confusional state—Methotrexate—lymphatic system cancer	0.000104	0.00052	CcSEcCtD
Carbamazepine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000103	0.000516	CcSEcCtD
Carbamazepine—Infection—Methotrexate—lymphatic system cancer	0.000102	0.000512	CcSEcCtD
Carbamazepine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000101	0.000506	CcSEcCtD
Carbamazepine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000101	0.000505	CcSEcCtD
Carbamazepine—Skin disorder—Methotrexate—lymphatic system cancer	9.98e-05	0.000501	CcSEcCtD
Carbamazepine—Hyperhidrosis—Methotrexate—lymphatic system cancer	9.93e-05	0.000499	CcSEcCtD
Carbamazepine—Anorexia—Methotrexate—lymphatic system cancer	9.79e-05	0.000492	CcSEcCtD
Carbamazepine—Hypotension—Methotrexate—lymphatic system cancer	9.6e-05	0.000482	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	9.36e-05	0.00047	CcSEcCtD
Carbamazepine—Insomnia—Methotrexate—lymphatic system cancer	9.29e-05	0.000466	CcSEcCtD
Carbamazepine—Paraesthesia—Methotrexate—lymphatic system cancer	9.22e-05	0.000463	CcSEcCtD
Carbamazepine—Dyspnoea—Methotrexate—lymphatic system cancer	9.16e-05	0.00046	CcSEcCtD
Carbamazepine—Somnolence—Methotrexate—lymphatic system cancer	9.13e-05	0.000458	CcSEcCtD
Carbamazepine—Dyspepsia—Methotrexate—lymphatic system cancer	9.04e-05	0.000454	CcSEcCtD
Carbamazepine—Decreased appetite—Methotrexate—lymphatic system cancer	8.93e-05	0.000448	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	8.87e-05	0.000445	CcSEcCtD
Carbamazepine—Fatigue—Methotrexate—lymphatic system cancer	8.85e-05	0.000445	CcSEcCtD
Carbamazepine—Pain—Methotrexate—lymphatic system cancer	8.78e-05	0.000441	CcSEcCtD
Carbamazepine—Feeling abnormal—Methotrexate—lymphatic system cancer	8.46e-05	0.000425	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	8.4e-05	0.000422	CcSEcCtD
Carbamazepine—Urticaria—Methotrexate—lymphatic system cancer	8.16e-05	0.00041	CcSEcCtD
Carbamazepine—Abdominal pain—Methotrexate—lymphatic system cancer	8.12e-05	0.000408	CcSEcCtD
Carbamazepine—Body temperature increased—Methotrexate—lymphatic system cancer	8.12e-05	0.000408	CcSEcCtD
Carbamazepine—Hypersensitivity—Methotrexate—lymphatic system cancer	7.57e-05	0.00038	CcSEcCtD
Carbamazepine—Asthenia—Methotrexate—lymphatic system cancer	7.37e-05	0.00037	CcSEcCtD
Carbamazepine—Pruritus—Methotrexate—lymphatic system cancer	7.27e-05	0.000365	CcSEcCtD
Carbamazepine—Diarrhoea—Methotrexate—lymphatic system cancer	7.03e-05	0.000353	CcSEcCtD
Carbamazepine—Dizziness—Methotrexate—lymphatic system cancer	6.79e-05	0.000341	CcSEcCtD
Carbamazepine—Vomiting—Methotrexate—lymphatic system cancer	6.53e-05	0.000328	CcSEcCtD
Carbamazepine—Rash—Methotrexate—lymphatic system cancer	6.48e-05	0.000325	CcSEcCtD
Carbamazepine—Dermatitis—Methotrexate—lymphatic system cancer	6.47e-05	0.000325	CcSEcCtD
Carbamazepine—Headache—Methotrexate—lymphatic system cancer	6.43e-05	0.000323	CcSEcCtD
Carbamazepine—Nausea—Methotrexate—lymphatic system cancer	6.1e-05	0.000306	CcSEcCtD
